Pulmonary Immunity and Immunopathology: Lessons from Respiratory Syncytial Virus

Overview

Journal Expert Rev Vaccines

Date 2008 Oct 11

PMID 18844597

Citations 39

Authors

Matthew R Olson

Steven M Varga

Affiliations

Soon will be listed here.

Abstract

Respiratory syncytial virus (RSV) is the leading cause of severe respiratory disease in infants and is an important source of morbidity and mortality in the elderly and immunocompromised. This review will discuss the humoral and cellular adaptive immune responses to RSV infection and how these responses are shaped in the immature immune system of the infant and the aged environment of the elderly. Furthermore, we will provide an overview of our current understanding of the role the various arms of the adaptive immune response play in mediating the delicate balance between the successful elimination of the virus from the host and the induction of immunopathology. Efficacious immunization against RSV remains a high priority within the field and we will highlight recent advances made in vaccine design.

Citing Articles

A Brief History of Human Challenge Studies (1900-2021) Emphasising the Virology, Regulatory and Ethical Requirements, Raison D'etre, Ethnography, Selection of Volunteers and Unit Design.

Oxford J, Catchpole A, Mann A, Bell A, Noulin N, Gill D Curr Top Microbiol Immunol. 2022; 445:1-32.

PMID: 35704095 DOI: 10.1007/82_2022_253.

Transdermal Immunization with Microparticulate RSV-F Virus-like Particles Elicits Robust Immunity.

DSa S, Braz Gomes K, Lovia Allotey-Babington G, Boyoglu C, Kang S, DSouza M Vaccines (Basel). 2022; 10(4).

PMID: 35455333 PMC: 9030121. DOI: 10.3390/vaccines10040584.

A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection.

Iwata-Yoshikawa N, Shiwa N, Sekizuka T, Sano K, Ainai A, Hemmi T Sci Adv. 2022; 8(1):eabh3827.

PMID: 34995117 PMC: 8741184. DOI: 10.1126/sciadv.abh3827.

Roles of the Fc Receptor γ-Chain in Inducing Protective Immune Responses after Heterologous Vaccination against Respiratory Syncytial Virus Infection.

Hwang H, Lee Y, Kim K, Seo H, Yang K, Cho H Vaccines (Basel). 2021; 9(3).

PMID: 33800349 PMC: 7998258. DOI: 10.3390/vaccines9030232.

Progress in the development of virus-like particle vaccines against respiratory viruses.

Quan F, Basak S, Chu K, Kim S, Kang S Expert Rev Vaccines. 2020; 19(1):11-24.

PMID: 31903811 PMC: 7103727. DOI: 10.1080/14760584.2020.1711053.

References

Bermingham A, Collins P . The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A. 1999; 96(20):11259-64. PMC: 18021. DOI: 10.1073/pnas.96.20.11259. View

Xiang Z, Li Y, Gao G, Wilson J, Ertl H . Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. J Immunol. 2003; 171(8):4287-93. DOI: 10.4049/jimmunol.171.8.4287. View

Shay D, Holman R, Roosevelt G, Clarke M, Anderson L . Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2000; 183(1):16-22. DOI: 10.1086/317655. View

Spann K, Tran K, Chi B, Rabin R, Collins P . Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J Virol. 2004; 78(8):4363-9. PMC: 374276. DOI: 10.1128/jvi.78.8.4363-4369.2004. View

Hammarlund E, Lewis M, Hansen S, Strelow L, Nelson J, Sexton G . Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003; 9(9):1131-7. DOI: 10.1038/nm917. View

Lee S, Miller S, Wright D, Rock M, Crowe Jr J . Tissue-specific regulation of CD8+ T-lymphocyte immunodominance in respiratory syncytial virus infection. J Virol. 2006; 81(5):2349-58. PMC: 1865932. DOI: 10.1128/JVI.01910-06. View

Prince G, Hemming V, Horswood R, Baron P, Chanock R . Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol. 1987; 61(6):1851-4. PMC: 254189. DOI: 10.1128/JVI.61.6.1851-1854.1987. View

Puthothu B, Forster J, Heinzmann A, Krueger M . TLR-4 and CD14 polymorphisms in respiratory syncytial virus associated disease. Dis Markers. 2007; 22(5-6):303-8. PMC: 3851085. DOI: 10.1155/2006/865890. View

Walsh E, Falsey A, Sullender W . Monoclonal antibody neutralization escape mutants of respiratory syncytial virus with unique alterations in the attachment (G) protein. J Gen Virol. 1998; 79 ( Pt 3):479-87. DOI: 10.1099/0022-1317-79-3-479. View

10.

Ishida N, Homma M . Sendai virus. Adv Virus Res. 1978; 23:349-83. DOI: 10.1016/s0065-3527(08)60103-7. View

11.

Waris M, Tsou C, Erdman D, Zaki S, Anderson L . Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol. 1996; 70(5):2852-60. PMC: 190142. DOI: 10.1128/JVI.70.5.2852-2860.1996. View

12.

Linton P, Haynes L, Klinman N, Swain S . Antigen-independent changes in naive CD4 T cells with aging. J Exp Med. 1996; 184(5):1891-900. PMC: 2192899. DOI: 10.1084/jem.184.5.1891. View

13.

Johnson T, Rothenberg M, Graham B . Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. J Leukoc Biol. 2008; 84(3):748-59. PMC: 2516895. DOI: 10.1189/jlb.0907621. View

14.

Ostler T, Davidson W, Ehl S . Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma. Eur J Immunol. 2002; 32(8):2117-23. DOI: 10.1002/1521-4141(200208)32:8<2117::AID-IMMU2117>3.0.CO;2-C. View

15.

Jiang S, Borthwick N, Morrison P, Gao G, Steward M . Virus-specific CTL responses induced by an H-2K(d)-restricted, motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus. J Gen Virol. 2002; 83(Pt 2):429-438. DOI: 10.1099/0022-1317-83-2-429. View

16.

Harcourt J, Karron R, Tripp R . Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis. 2004; 190(11):1936-40. DOI: 10.1086/425516. View

17.

Varga S, Wissinger E, Braciale T . The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J Immunol. 2000; 165(11):6487-95. DOI: 10.4049/jimmunol.165.11.6487. View

18.

Fuller H, Del Mar C . Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev. 2006; (4):CD004883. DOI: 10.1002/14651858.CD004883.pub2. View

19.

Olson M, Varga S . CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol. 2007; 179(8):5415-24. DOI: 10.4049/jimmunol.179.8.5415. View

20.

Fishaut M, Tubergen D, McIntosh K . Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr. 1980; 96(2):179-86. DOI: 10.1016/s0022-3476(80)80799-2. View